Moderna announced the preliminary results of a Phase I/II dose optimization and extension study to assess the efficacy and safety of mRNA-3927, an investigational mRNA treatment for propionic acidemia ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback